查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1747050

日本抗真菌药物市场报告（按药物类别（唑类、棘白菌素类、多烯类、烯丙胺类等）、适应症（皮癣菌病、曲霉病、念珠菌病等）和地区划分）2025-2033

Japan Antifungal Drugs Market Report by Drug Classe (Azoles, Echinocandins, Polyenes, Allylamines, and Others), Indication (Dermatophytosis, Aspergillosis, Candidiasis, Others), and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 118 Pages | 商品交期: 5-7个工作天内

价格
简介目录

2024年，日本抗真菌药物市场规模达10.8亿美元。展望未来， IMARC Group预计到2033年，该市场规模将达到16.3亿美元，2025-2033年期间的复合年增长率（CAGR）为4.47%。真菌感染病例的增加，归因于多种因素，例如免疫功能低下人群的增加、人口老化、免疫抑制药物的广泛使用等，正在推动市场的发展。

抗真菌药物是用来对抗人类、动物和植物真菌感染的药物化合物。真菌感染的症状从轻微的皮肤病到严重的、危及生命的全身性疾病。这些药物透过靶向真菌细胞生长和功能的各个方面发挥作用，抑制其复製和扩散能力。抗霉菌药物有多种类别，包括唑类、多烯类、棘白菌素类和烯丙胺类。唑类，例如氟康唑和伊曲康唑，会干扰真菌细胞膜的合成。多烯类，例如两性霉素B，会直接破坏真菌细胞膜。棘白菌素类，包括卡泊芬净，会抑制细胞壁的形成。烯丙胺类，例如特比萘芬，会干扰真菌酶的活性。选择合适的抗真菌药物取决于感染的类型和严重程度，以及患者的健康状况。有些抗真菌药物可在非处方药中外用，而有些则需要处方才能用于全身感染。依照规定使用这些药物至关重要，以确保有效性并最大限度地降低出现抗药性真菌菌株的风险。

日本抗真菌药物市场趋势：

日本抗真菌药物市场有望实现大幅成长，这主要得益于几个相互关联的因素。首先，真菌感染发生率的上升是关键驱动因素。随着真菌病原体的抗药性增强，对创新抗真菌疗法的需求也日益增加。此外，老龄人口的成长（通常免疫系统较弱）也增加了老年人对真菌感染的易感性，这进一步推动了市场扩张。其次，医学研究和生物技术的进步为新型抗真菌药物的开发铺平了道路。对真菌生物学理解的突破以及新药物靶点的发现，带来了源源不绝的创新疗法。因此，製药公司正大力投资研发，促进市场成长。此外，各国政府和医疗机构在控制真菌感染传播方面提供的资金和优惠政策支持不断增加，预计将在预测期内推动日本抗真菌药物市场的发展。

日本抗真菌药物市场细分：

药物类别洞察：

  • 唑类
    • 伏立康唑（Vfend）
    • 泊沙康唑（Noxafil）
    • 克霉唑（凯妮汀）
    • 艾沙康唑（Cresemba）
    • 其他的
  • 棘白菌素类
    • 卡泊芬净（Cancidas）
    • 米卡芬净（Mycamine/ Funguard）
    • 其他的
  • 多烯类
    • 两性霉素（AmBisome）
    • 其他的
  • 烯丙胺
    • 特比萘芬（Lamisil）
    • 其他的
  • 其他的

指示见解：

  • 皮癣菌病
  • 曲菌病
  • 念珠菌病
    • 侵袭性念珠菌病
    • 外阴阴道念珠菌病（VVC）
    • 口腔/咽喉/食道念珠菌病
    • 其他的
  • 其他的

竞争格局：

市场研究报告也对竞争格局进行了全面的分析。报告涵盖了市场结构、关键参与者定位、最佳制胜策略、竞争仪錶板和公司评估象限等竞争分析。此外，报告还提供了所有主要公司的详细资料。

本报告回答的关键问题：

  • 日本抗真菌药物市场迄今表现如何，未来几年将如何表现？
  • COVID-19 对日本抗真菌药物市场有何影响？
  • 日本抗真菌药物市场按药物类别划分是怎样的？
  • 日本抗真菌药物市场根据适应症的分布是怎样的？
  • 日本抗霉菌药物市场的价值链分为哪些阶段？
  • 日本抗真菌药物的关键驱动因素和挑战是什么？
  • 日本抗霉菌药物市场的结构是怎么样的？主要参与者是谁？
  • 日本抗霉菌药物市场的竞争程度如何？

本报告回答的关键问题：

  • 日本抗真菌药物市场迄今表现如何，未来几年将如何表现？
  • COVID-19 对日本抗真菌药物市场有何影响？
  • 日本抗真菌药物市场按药物类别划分是怎样的？
  • 日本抗真菌药物市场根据适应症的分布是怎样的？
  • 日本抗霉菌药物市场的价值链分为哪些阶段？
  • 日本抗真菌药物的关键驱动因素和挑战是什么？
  • 日本抗霉菌药物市场的结构是怎么样的？主要参与者是谁？
  • 日本抗霉菌药物市场的竞争程度如何？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：日本抗霉菌药物市场 - 简介

  • 概述
  • 市场动态
  • 产业趋势
  • 竞争情报

第五章：日本抗霉菌药物市场概况

  • 历史与当前市场趋势（2019-2024）
  • 市场预测（2025-2033）

第 6 章：日本抗真菌药物市场 - 细分：按药物类别

  • 唑类
    • 概述
    • 市场区隔
      • 伏立康唑（Vfend）
      • 泊沙康唑（Noxafil）
      • 克霉唑（凯妮汀）
      • 艾沙康唑（Cresemba）
      • 其他的
  • 棘白菌素类
    • 概述
    • 市场区隔
      • 卡泊芬净（Cancidas）
      • 米卡芬净（Mycamine/ Funguard）
      • 其他的
  • 多烯类
    • 概述
    • 市场区隔
      • 两性霉素（AmBisome）
      • 其他的
  • 烯丙胺
    • 概述
    • 市场区隔
      • 特比萘芬（Lamisil）
      • 其他的
  • 其他的

第七章：日本抗霉菌药物市场-细分：按适应症

  • 皮癣菌病
    • 概述
  • 曲菌病
    • 概述
  • 念珠菌病
    • 概述
    • 市场区隔
      • 侵袭性念珠菌病
      • 碳酸钙
      • 外阴阴道念珠菌病（VVC）
      • 口腔/咽喉/食道念珠菌病
      • 其他的
  • 其他的

第 8 章：日本抗霉菌药物市场 - 竞争格局

  • 概述
  • 市场结构
  • 市场参与者定位
  • 最佳获胜策略
  • 竞争仪錶板
  • 公司评估象限

第九章：关键参与者简介

  • Company A
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company B
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company C
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company D
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company E
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events

第十章：日本抗真菌药物市场-产业分析

  • 驱动因素、限制因素和机会
    • 概述
    • 驱动程式
    • 限制
    • 机会
  • 波特五力分析
    • 概述
    • 买家的议价能力
    • 供应商的议价能力
    • 竞争程度
    • 新进入者的威胁
    • 替代品的威胁
  • 价值链分析

第 11 章：附录

简介目录
Product Code: SR112025A18738

Japan antifungal drugs market size reached USD 1.08 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 1.63 Billion by 2033, exhibiting a growth rate (CAGR) of 4.47% during 2025-2033. The increasing cases of fungal infections, attributed to several factors, such as a growing population of immunocompromised individuals, aging people, the widespread use of immunosuppressive drug, etc., are driving the market.

Antifungal drugs are pharmaceutical compounds designed to combat fungal infections in humans, animals, and plants. Fungal infections can range from mild skin conditions to severe, life-threatening systemic illnesses. These drugs work by targeting various aspects of fungal cell growth and function, inhibiting their ability to replicate and spread. There are several classes of antifungal drugs, including azoles, polyenes, echinocandins, and allylamines. Azoles, such as fluconazole and itraconazole, interfere with fungal cell membrane synthesis. Polyenes, like amphotericin B, disrupt fungal cell membranes directly. Echinocandins, including caspofungin, inhibit cell wall formation. Allylamines, such as terbinafine, interfere with fungal enzyme activity. Choosing the appropriate antifungal drug depends on the type and severity of the infection, as well as the patient's health status. Some antifungals are available over-the-counter for topical use, while others require a prescription for systemic infections. It's crucial to use these drugs as prescribed to ensure effectiveness and minimize the risk of drug-resistant fungal strains emerging.

Japan Antifungal Drugs Market Trends:

The antifungal drugs market in Japan is poised for significant growth, primarily due to several interconnected factors. Firstly, the rising incidence of fungal infections serves as a crucial driver. As fungal pathogens become more resistant, the demand for innovative antifungal therapies intensifies. Moreover, the growing elderly population, often with compromised immune systems, increases susceptibility to fungal infections, further propelling market expansion. Secondly, advancements in medical research and biotechnology have paved the way for novel antifungal drug development. Breakthroughs in understanding fungal biology and the discovery of new drug targets have led to a steady influx of innovative therapies. Consequently, pharmaceutical companies are investing heavily in R&D, fostering market growth. Additionally, the rising support from various governments and healthcare organizations in the form of funding and favorable policies to control the spread of fungal infections is expected to drive the antifungal drugs market in Japan during the forecast period.

Japan Antifungal Drugs Market Segmentation:

Drug Class Insights:

  • Azoles
    • Voriconazole (Vfend)
    • Posaconazole (Noxafil)
    • Clotrimazole (Canesten)
    • Isavuconazole (Cresemba)
    • Others
  • Echinocandins
    • Caspofungin (Cancidas)
    • Micafungin (Mycamine/ Funguard)
    • Others
  • Polyenes
    • Amphotericin (AmBisome)
    • Others
  • Allylamines
    • Terbinafine (Lamisil)
    • Others
  • Others

Indication Insights:

  • Dermatophytosis
  • Aspergillosis
  • Candidiasis
    • Invasive Candidiasis
    • Vulvovaginal Candidiasis (VVC)
    • Mouth/Throat/Esophageal Candidiasis
    • Others
  • Others

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan antifungal drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan antifungal drugs market?
  • What is the breakup of the Japan antifungal drugs market on the basis of drug class?
  • What is the breakup of the Japan antifungal drugs market on the basis of indication?
  • What are the various stages in the value chain of the Japan antifungal drugs market?
  • What are the key driving factors and challenges in the Japan antifungal drugs?
  • What is the structure of the Japan antifungal drugs market and who are the key players?
  • What is the degree of competition in the Japan antifungal drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Antifungal Drugs Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Antifungal Drugs Market Landscape

  • 5.1 Historical and Current Market Trends (2019-2024)
  • 5.2 Market Forecast (2025-2033)

6 Japan Antifungal Drugs Market - Breakup by Drug Class

  • 6.1 Azoles
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2019-2024)
    • 6.1.3 Market Segmentation
      • 6.1.3.1 Voriconazole (Vfend)
      • 6.1.3.2 Posaconazole (Noxafil)
      • 6.1.3.3 Clotrimazole (Canesten)
      • 6.1.3.4 Isavuconazole (Cresemba)
      • 6.1.3.5 Others
    • 6.1.4 Market Forecast (2025-2033)
  • 6.2 Echinocandins
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2019-2024)
    • 6.2.3 Market Segmentation
      • 6.2.3.1 Caspofungin (Cancidas)
      • 6.2.3.2 Micafungin (Mycamine/ Funguard)
      • 6.2.3.3 Others
    • 6.2.4 Market Forecast (2025-2033)
  • 6.3 Polyenes
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2019-2024)
    • 6.3.3 Market Segmentation
      • 6.3.3.1 Amphotericin (AmBisome)
      • 6.3.3.2 Others
    • 6.3.4 Market Forecast (2025-2033)
  • 6.4 Allylamines
    • 6.4.1 Overview
    • 6.4.2 Historical and Current Market Trends (2019-2024)
    • 6.4.3 Market Segmentation
      • 6.4.3.1 Terbinafine (Lamisil)
      • 6.4.3.2 Others
    • 6.4.4 Market Forecast (2025-2033)
  • 6.5 Others
    • 6.5.1 Historical and Current Market Trends (2019-2024)
    • 6.5.2 Market Forecast (2025-2033)

7 Japan Antifungal Drugs Market - Breakup by Indication

  • 7.1 Dermatophytosis
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2019-2024)
    • 7.1.3 Market Forecast (2025-2033)
  • 7.2 Aspergillosis
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2019-2024)
    • 7.2.3 Market Forecast (2025-2033)
  • 7.3 Candidiasis
    • 7.3.1 Overview
    • 7.3.2 Historical and Current Market Trends (2019-2024)
    • 7.3.3 Market Segmentation
      • 7.3.3.1 Invasive Candidiasis
      • 7.3.3.2 Calcium Carbonate
      • 7.3.3.3 Vulvovaginal Candidiasis (VVC)
      • 7.3.3.4 Mouth/Throat/Esophageal Candidiasis
      • 7.3.3.5 Others
    • 7.3.4 Market Forecast (2025-2033)
  • 7.4 Others
    • 7.4.1 Historical and Current Market Trends (2019-2024)
    • 7.4.2 Market Forecast (2025-2033)

8 Japan Antifungal Drugs Market - Competitive Landscape

  • 8.1 Overview
  • 8.2 Market Structure
  • 8.3 Market Player Positioning
  • 8.4 Top Winning Strategies
  • 8.5 Competitive Dashboard
  • 8.6 Company Evaluation Quadrant

9 Profiles of Key Players

  • 9.1 Company A
    • 9.1.1 Business Overview
    • 9.1.2 Product Portfolio
    • 9.1.3 Business Strategies
    • 9.1.4 SWOT Analysis
    • 9.1.5 Major News and Events
  • 9.2 Company B
    • 9.2.1 Business Overview
    • 9.2.2 Product Portfolio
    • 9.2.3 Business Strategies
    • 9.2.4 SWOT Analysis
    • 9.2.5 Major News and Events
  • 9.3 Company C
    • 9.3.1 Business Overview
    • 9.3.2 Product Portfolio
    • 9.3.3 Business Strategies
    • 9.3.4 SWOT Analysis
    • 9.3.5 Major News and Events
  • 9.4 Company D
    • 9.4.1 Business Overview
    • 9.4.2 Product Portfolio
    • 9.4.3 Business Strategies
    • 9.4.4 SWOT Analysis
    • 9.4.5 Major News and Events
  • 9.5 Company E
    • 9.5.1 Business Overview
    • 9.5.2 Product Portfolio
    • 9.5.3 Business Strategies
    • 9.5.4 SWOT Analysis
    • 9.5.5 Major News and Events

10 Japan Antifungal Drugs Market - Industry Analysis

  • 10.1 Drivers, Restraints, and Opportunities
    • 10.1.1 Overview
    • 10.1.2 Drivers
    • 10.1.3 Restraints
    • 10.1.4 Opportunities
  • 10.2 Porters Five Forces Analysis
    • 10.2.1 Overview
    • 10.2.2 Bargaining Power of Buyers
    • 10.2.3 Bargaining Power of Suppliers
    • 10.2.4 Degree of Competition
    • 10.2.5 Threat of New Entrants
    • 10.2.6 Threat of Substitutes
  • 10.3 Value Chain Analysis

11 Appendix